16 September 2026 editorial review · Item
CNP-103 tolerogenic nanoparticles: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: new record; substantive review 16 September 2026.
- Scope and findings: Added programme item and corrected associated trial. Checked September 11 registry and publisher-deposited ADA abstract through Crossref: six-adult cohort, early dosing, no serious events reported, no C-peptide efficacy result. Company pipeline and current recruitment page distinguish mechanism/designation from clinical evidence.
- Primary sources checked: NCT06783309 — study record (registry); ADA 2026 abstract 2419-P: CNP-103 first-in-human study (conference); COUR pipeline — CNP-103 intended immune-tolerance mechanism (manufacturer); COUR CNP-103 clinical trial information (manufacturer).
- Limits: Conference report is not full trial outcomes or proof of overall safety. Sponsor page gives conflicting site counts and participation duration; no exact counts repeated. Four recombinant proteins are described but precise payload coverage is not independently validated.